Search - tctmd.com

Displaying 61 - 80 of 124

Sort: Relevancy | Date

News Conference News HFSA 2022

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

L.A. McKeown

October 07, 2022

News Conference News TCT 2022

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

L.A. McKeown

September 23, 2022

News Daily News

Most Patient-Reported Outcome Measures in CVD Fall Short

L.A. McKeown

September 23, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News EuroPCR 2022

TriCLASP: Tricuspid Repair With Pascal Safe, Effective at 30 days

Yael L. Maxwell

May 19, 2022

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Conference News ACC 2022

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

L.A. McKeown

April 07, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

Yael L. Maxwell

April 02, 2022

SODIUM-HF: No Impact of Dietary Salt Restriction on Death or Hospitalization

News Conference News ACC 2022

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

L.A. McKeown

April 02, 2022

News Conference News THT 2022

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Shelley Wood

February 02, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

News Opinion CV Team Dispatch

December 2021 News Roundup

L.A. McKeown

December 01, 2021

News Conference News AHA 2021

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Todd Neale

November 17, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Todd Neale

September 13, 2021

News Conference News EuroPCR 2021

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

Caitlin E. Cox

May 21, 2021

Advertisement

REDWOOD-HCM OLE: Aficamten Improves Patient-Measured Health Status

Pre-AVR Cardiac Damage in PARTNER Patients Linked to Poorer QoL at 1 Year

Most Patient-Reported Outcome Measures in CVD Fall Short

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Dapagliflozin Boosts Health Status Across LVEF Range

TriCLASP: Tricuspid Repair With Pascal Safe, Effective at 30 days

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

QoL Gains Within 15 Days in Acute HF With Empagliflozin: EMPULSE Analysis

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Mavacamten Slashes Need for Septal Reduction in Obstructive HCM: VALOR-HCM

SODIUM-HF: No Impact of Tighter Dietary Salt Restriction on Death or Hospitalization

Early Positive Signals From RELIEVE-HF Shift Discussion to Atrial Shunt Size

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

December 2021 News Roundup

Empagliflozin Retains Benefits in ‘True’ HFpEF Patients

Canagliflozin Improves Quality of Life in HF Patients

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Tricuspid Trio: TRISCEND, CLASP TR, and TriBAND Studies Show Advances

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content